2-Thiopyrimidinones
AssigneePfizer Inc.
InventorsPhilip A. Carpino, Edward L. Conn, Robert L. Dow, Matthew S. Dowling, David Hepworth, Daniel Wei-Shung Kung, Suvi Orr, Benjamin N. Rocke, Roger B. Ruggeri, Matthew F. Sammons, Joseph S. Warmus, Yan Zhang
Life of this patent
Estimating the term…
Abstract
Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Claims10
-14. (canceled)
A method of treating cardiovascular conditions comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 23 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.
A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 23 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.
A pharmaceutical combination composition comprising:
- a therapeutically effective amount of a composition comprising:
- a first compound, said first compound being a compound of claim 23, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;
- a second compound, said second compound being an angiotensin converting enzyme inhibitor, a HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, a Factor Xa inhibitor or warfarin;
- and
- a pharmaceutical carrier, vehicle or diluents.
-22. (canceled)
The compound N-(2-aminoethyl)-2-[6-(2,4-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl]acetamide or a pharmaceutically acceptable salt thereof.
The compound having the Formula
-29. (canceled)
Dependencies are inferred from the claim text.